Novo Nordisk has filed for approval to extend the ... a childhood obesity specialist at the University of Minnesota Medical School in Minneapolis, pointed out that, left untreated, childhood ...
Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...
The 'big three' insulin producers Novo Nordisk, Eli Lilly ... Mississippi, and Minnesota. "We're fighting back against drug companies and PBMs that unacceptably and artificially inflate the ...
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...
NEW YORK, NY / ACCESS Newswire / February 23, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Novo Nordisk (NYSE: NVO) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly) that's also probably bad news for Hims & Hers Health (NYSE: HIMS).
The FDA today declared the national deficit of GLP-1 diet drugs at an end. Well, at least for Novo Nordisk's Ozempic and Wegovy. Novo Nordisk sales should be going up, and Hims & Hers Health's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback